On July 8th, Shengnuo Medicine-B announced on the HKEx that the company subscribed to a total of 20 million US dollars (excluding transaction fees) for TradArt Flagship Investment SPC's independent investment portfolio and redeemed 0.2 million US dollars as of the announcement date. Please use your Futubull account to access the feature.
圣诺医药-B：预计投资基金可能出现重大亏损，已成立调查委员会
Shengnuo Medicine-B: expects significant losses from investment funds, and has formed an investigation committee.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.